Amgen Inc.
KIF18A INHIBITORS
Last updated:
Abstract:
The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
20 Dec 2019
Issue date:
6 Jan 2022